• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Import Refusal Report

  • Print
  • Share
  • E-mail
-

Refusal Actions by FDA as Recorded in OASIS

for 64-Human and Animal Drugs


Entry/doc/line/sfx Refusal Date Product
Code
Manufacturer
FEI
Manufacturer
Name
Manufacturer
Country/Area
D76-1062451-3/2/1 09-Apr-2002 64ABR20 1000386375 Schering Plough Sa De Cv Mexico
 
D76-1062451-3/3/1 09-Apr-2002 64ABR20 1000386375 Schering Plough Sa De Cv Mexico
 
D76-1062451-3/1/1 09-Apr-2002 64ABR20 1000386375 Schering Plough Sa De Cv Mexico
 
110-7988905-1/2/1 03-Apr-2002 64EAY99 3001190779 Mcewen Laboratories Limited United Kingdom
 
F11-2363771-4/1/1 05-Apr-2002 64FAA99 3003616012 Bangkok Adventist Hospital Thailand
 
DQ4-8983245-0/7/1 01-Apr-2002 64GDB28 3002806439 Pfizer Canada Inc. Canada
 
F11-2363871-2/5/1 05-Apr-2002 64HAA99 3003616986 Jih-Jung Wang Taiwan
 
M05-0322619-9/1/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322619-9/2/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322619-9/3/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322619-9/4/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322619-9/5/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322619-9/6/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322619-9/7/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322628-0/1/1 08-Apr-2002 64HDL99 1000174169 Smithkline Beecham United Kingdom
 
M05-0322628-0/2/1 08-Apr-2002 64HDL99 1000174169 Smithkline Beecham United Kingdom
 
M05-0322796-5/1/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322797-3/1/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322797-3/2/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322797-3/3/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322797-3/4/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322797-3/5/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0322797-3/6/1 08-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0108672-8/1/1 08-Apr-2002 64HDL99 3000251595 Glaxo De Mexico S.A. De C.V. Mexico
 
M05-0108681-9/1/1 08-Apr-2002 64HDL99 3002825550 Smihtkline Beecham International (Panama), S.A. Panama
 
M05-0108687-6/1/1 08-Apr-2002 64HDL99 3003262904 Glaxo Operations UK Limited United Kingdom
 
M05-0108687-6/2/1 08-Apr-2002 64HDL99 3003262904 Glaxo Operations UK Limited United Kingdom
 
M05-0108689-2/1/1 08-Apr-2002 64HDL99 3003885753 Glaxo Wellcome South Africa (Pty) Ltd. South Africa
 
M05-0109042-3/1/1 16-Apr-2002 64HDL99 1000174169 Smithkline Beecham United Kingdom
 
M05-0109042-3/2/1 16-Apr-2002 64HDL99 1000174169 Smithkline Beecham United Kingdom
 
M05-0109080-3/1/1 16-Apr-2002 64HDL99 3003262904 Glaxo Operations UK Limited United Kingdom
 
M05-0109127-2/1/1 16-Apr-2002 64HDL99 1000174169 Smithkline Beecham United Kingdom
 
M05-0109145-4/1/1 16-Apr-2002 64HDL99 3003262904 Glaxo Operations UK Limited United Kingdom
 
M05-0109145-4/2/1 16-Apr-2002 64HDL99 3003262904 Glaxo Operations UK Limited United Kingdom
 
M05-0109160-3/1/1 16-Apr-2002 64HDL99 3003262904 Glaxo Operations UK Limited United Kingdom
 
M05-0109163-7/1/1 16-Apr-2002 64HDL99 1000174169 Smithkline Beecham United Kingdom
 
M05-0108645-4/1/1 16-Apr-2002 64HDL99 3003262904 Glaxo Operations UK Limited United Kingdom
 
M05-0109182-7/1/1 17-Apr-2002 64HDL99 3003724366 GlaxoSmithKline Panama S.A. Panama
 
M05-0323921-8/1/1 17-Apr-2002 64HDL99 3002952995 Smithkline Beecham Costa Rica S.A. Costa Rica
 
M05-0109216-3/1/1 25-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0323953-1/1/1 29-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0323953-1/2/1 29-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0323953-1/3/1 29-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0323953-1/4/1 29-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0323953-1/5/1 29-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0323953-1/6/1 29-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
M05-0323953-1/7/1 29-Apr-2002 64HDL99 3003878140 GlaxoSmithKline Inc. Canada
 
582-6622817-9/1/1 12-Apr-2002 64LAY06 3002996872 Crystal Pharma, S.A.U. Spain
 
F11-2362014-0/1/1 13-Apr-2002 64LIY50 3001164052 Henan Lihua Pharmaceutical Co., Ltd. China
 
XXX-0045043-8/1/1 02-Apr-2002 64RCP99 3000298408 Serono Pharma S.P.A. Italy
 
XXX-0045043-8/1/2 02-Apr-2002 64RCP99 3003560844 Ferring SpA Italy
 
110-8007698-7/1/1 09-Apr-2002 64RCP99 3003548081 Natacha Carty Netherlands Antilles
 
582-9316850-5/1/1 06-Apr-2002 64RCY99 2917293 Genentech, Inc. United States
 
606-0069189-7/1/1 10-Apr-2002 64RCY99 3003169366 Shanghai Freemen LifeScience Co., Ltd. China
 
582-3454437-6/1/1 11-Apr-2002 64RIK99 3002808086 Bayer Pharma AG Germany
 
-
-